Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMACYW6)

Drug Name

NKTR-214 Drug Info

Synonyms

bempegaldesleukin

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 2 receptor beta (IL2RB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKTR 214	DM376WT	Melanoma	2C30	Phase 3	[3]
AFTVac	DMD3XMG	Glioblastoma multiforme	2A00.0	Phase 2	[4]
Leukocyte interleukin	DM2B0TJ	Head and neck cancer	2D42	Phase 1	[5]
DAB-486-IL-2	DM54T8J	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 2 receptor beta (IL2RB)	TT9721Y	IL2RB_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
5	Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64.
6	Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol. 1992 Mar;22(3):697-702.